GO:0030273 melanin-concentrating hormone receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030273 (melanin-concentrating hormone receptor activity) is a molecular function defined as combining with the cyclic peptide hormone melanin-concentrating hormone (MCH) to initiate a change in cell activity.
• The principal receptor is MCHR1 (also known as GPR24/SLC-1), a G protein-coupled receptor that binds MCH and is expressed in brain, brown adipose tissue and primary cilia of dorsal raphe neurons.
• MCHR1 signaling regulates energy balance, locomotor activity, arousal and reward-related behaviors, and is modulated by neurotensin and nicotine experience.
• MCHR1 is a validated drug target for obesity, metabolic disease and psychiatric conditions, driving extensive medicinal chemistry for antagonists with low hERG liability.
• Conditional deletion of MCHR1 from GABAergic neurons increases locomotor activity, demonstrating cell-type-specific functions.
• Research on this receptor uses knockout mice, point-mutation and knock-in models, receptor autoradiography, ciliary imaging, and CRISPR-based cellular screens.
Description
GO:0030273, melanin-concentrating hormone receptor activity, is a molecular function term in the Gene Ontology that describes the binding of the cyclic peptide hormone melanin-concentrating hormone (MCH) to its receptor, thereby initiating a change in cell activity. This activity is mediated primarily by the MCH receptor 1 (MCHR1), a class A G protein-coupled receptor (GPCR) that couples to G proteins and downstream signaling cascades. The receptor is widely expressed in the central nervous system and in peripheral tissues such as brown adipose tissue, positioning it at the interface of energy homeostasis and neural circuit control. For researchers, GO:0030273 is important because MCHR1 signaling influences feeding, body weight, locomotor activity, arousal and reward processing. Dysregulation of this receptor has been linked to obesity, metabolic disorders and neuropsychiatric conditions, making it a high-value target for drug discovery. Understanding the precise molecular interactions, cellular localization and regulatory inputs of MCHR1 is essential for developing selective therapeutics with minimal off-target effects. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to provide a research-grade overview of the receptor's mechanism, key genes, disease relevance and experimental models, including CRISPR-based approaches for functional interrogation.
melanin-concentrating hormone receptor activity At A Glance
| GO ID | GO:0030273 |
|---|---|
| GO term | melanin-concentrating hormone receptor activity |
| Ontology | molecular_function |
| Synonym | MCH receptor |
| Definition | Combining with the cyclic peptide hormone melanin-concentrating hormone to initiate a change in cell activity. |
| Major function | Binds MCH and initiates intracellular signaling, primarily via MCHR1 GPCR. |
| Primary receptor | MCHR1 (GPR24/SLC-1), a class A GPCR. |
| Tissue expression | Brain (including dorsal raphe neurons), brown adipose tissue, and other peripheral tissues. |
| Subcellular localization | Plasma membrane and primary cilia of specific neuronal populations. |
What Is GO:0030273?
Melanin-concentrating hormone receptor activity (GO:0030273) is the molecular function of a receptor protein that selectively binds the cyclic peptide hormone melanin-concentrating hormone (MCH) and, upon binding, triggers intracellular signaling that changes the behavior or state of the cell. This activity is synonymous with MCH receptor function and is canonically executed by the MCHR1 GPCR, which transduces hormone binding into G protein-mediated downstream events.
Why Is melanin-concentrating hormone receptor activity Important in Cell Biology?
Melanin-concentrating hormone receptor activity is a central node in the neuroendocrine control of energy balance, arousal and motivated behavior, and its pharmacological modulation has been pursued for obesity and metabolic disorders. Because MCHR1 is a tractable GPCR with well-defined endogenous ligand chemistry, it serves as a model system for understanding how peptide hormone receptors integrate peripheral metabolic signals with central neural circuits.
• Regulates feeding and energy homeostasis through hypothalamic and brainstem circuits.
• Controls locomotor activity and arousal, with cell-type-specific effects in GABAergic neurons.
• Modulates reward-related behaviors, including nicotine experience-dependent locomotion.
• Expressed in brown adipose tissue, linking MCH signaling to thermogenesis and metabolic rate.
• Localized to primary cilia of dorsal raphe neurons, implicating ciliary signaling in mood regulation.
• Is a validated drug target for obesity and metabolic syndrome, with extensive antagonist development.
• Interacts with neurotensin signaling, which inhibits MCH signaling and enhances arousal.
• Provides a paradigm for studying GPCR structure-activity relationships and hERG liability.
• Offers opportunities for CRISPR-based functional genomics in metabolic and neuropsychiatric research.
Molecular Mechanism of melanin-concentrating hormone receptor activity
Ligand Binding and Receptor Activation
In simple terms: The hormone MCH docks into the receptor like a key in a lock, switching the receptor on.
Melanin-concentrating hormone (MCH) is a cyclic peptide hormone that binds with high affinity to MCHR1, a class A GPCR. The binding event induces conformational changes in the receptor, enabling it to act as a guanine nucleotide exchange factor for heterotrimeric G proteins. This activation step is the defining molecular event of GO:0030273 and is the basis for receptor autoradiography and ligand-binding assays used in drug discovery.
G Protein Coupling and Downstream Signaling
In simple terms: Once switched on, the receptor activates G proteins that relay the signal inside the cell.
Activated MCHR1 couples primarily to Gq/11 and Gi/o proteins, leading to phospholipase C activation, calcium mobilization and inhibition of adenylyl cyclase. These second messenger changes alter neuronal excitability and gene expression programs relevant to energy balance and arousal. The specific G protein repertoire and downstream effectors can vary by cell type, as shown by differential effects of MCHR1 deletion in GABAergic neurons.
Receptor Localization and Ciliary Signaling
In simple terms: The receptor sits on tiny hair-like structures on some neurons, where it can sense signals in a specialized compartment.
MCHR1 is localized not only to the plasma membrane but also to primary cilia of dorsal raphe neurons, a subcellular domain enriched in GPCR signaling machinery. This ciliary localization suggests that MCH signaling may be compartmentalized, influencing serotonergic circuits and mood-related behaviors. The presence of MCHR1 in primary cilia also highlights the importance of trafficking and scaffolding proteins in regulating receptor activity.
Regulation by Neurotensin and Other Modulators
In simple terms: Other brain signals can turn down the receptor's activity, fine-tuning its effects.
Neurotensin enhances locomotor activity and arousal while inhibiting melanin-concentrating hormone signaling, indicating cross-talk between neuropeptide systems. This inhibition may occur through heterologous desensitization or downstream signaling interference. Additionally, nicotine experience differentially alters MCHR1-dependent locomotor behavior in female and male rats, suggesting sex-specific regulatory mechanisms.
Pharmacological Modulation and Antagonist Design
In simple terms: Drugs can block the receptor to reduce its activity, which is being explored for obesity treatment.
Small-molecule MCHR1 antagonists have been optimized for potency and low hERG channel activity, a critical safety parameter for cardiovascular risk. Structure-based design using saturated nitrogen-containing heterocycles has yielded novel ligands with improved drug-like properties. These antagonists are valuable tools for probing MCHR1 function in vivo and for developing therapeutics for metabolic disorders.
Key Genes Involved in GO:0030273 melanin-concentrating hormone receptor activity
The following genes and proteins are central to melanin-concentrating hormone receptor activity, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MCHR1 | Primary receptor for MCH; mediates GO:0030273 | Knockout and conditional deletion models reveal roles in locomotion and energy balance |
| PMCH | Precursor protein for melanin-concentrating hormone (MCH) | Ligand source for receptor activation studies |
| GNAQ | Gq alpha subunit; couples to MCHR1 | Downstream signaling mediator in receptor activation assays |
| GNAI1 | Gi alpha subunit; inhibits adenylyl cyclase downstream of MCHR1 | Modulates cAMP-dependent pathways in MCH signaling |
| NTS | Neurotensin; inhibits MCH signaling | Cross-talk studies with MCHR1 in arousal and locomotion |
| NTSR1 | Neurotensin receptor 1; mediates neurotensin effects | Potential modulator of MCHR1 signaling |
| GPR24 | Alternative name for MCHR1 | Used in receptor expression and localization studies |
| SLC-1 | Alternative name for MCHR1 | Historical nomenclature in MCH receptor discovery |
| ADCY1 | Adenylyl cyclase; downstream effector of Gi/o | Measures cAMP changes upon MCHR1 activation |
| PLCB1 | Phospholipase C beta; downstream effector of Gq | Calcium mobilization assays for MCHR1 activity |
| ARRB1 | Beta-arrestin 1; regulates receptor desensitization | Potential role in MCHR1 internalization |
| ARRB2 | Beta-arrestin 2; regulates receptor desensitization | Potential role in MCHR1 trafficking |
| GNB1 | G protein beta subunit; part of heterotrimeric G proteins | Required for MCHR1 signal transduction |
| GNG2 | G protein gamma subunit; part of heterotrimeric G proteins | Required for MCHR1 signal transduction |
| PRKACA | cAMP-dependent protein kinase; downstream of Gi/o | Mediates phosphorylation events in MCH signaling |
| PRKCA | PKC alpha; downstream of Gq | Mediates calcium-dependent signaling in MCHR1 activation |
| CAMK2A | Calcium/calmodulin-dependent kinase II; downstream of Gq | Potential role in neuronal plasticity upon MCHR1 activation |
| KCNQ2 | Potassium channel; modulated by MCHR1 signaling | Influences neuronal excitability in MCH-responsive circuits |
How Is melanin-concentrating hormone receptor activity Regulated?
MCHR1 activity is regulated at multiple levels. Neurotensin inhibits MCH signaling, likely through heterologous desensitization or downstream interference. Nicotine experience differentially modulates MCHR1-dependent locomotor behavior in a sex-dependent manner, suggesting hormonal or circuit-level regulation. Receptor desensitization and internalization are mediated by beta-arrestins and kinases, although direct evidence for MCHR1 in these processes is still emerging. Additionally, ciliary localization may restrict receptor signaling to specific subcellular compartments, adding another layer of regulation.
melanin-concentrating hormone receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MCHR1 | Obesity and metabolic syndrome | MCHR1 knockout mice; diet-induced obesity models |
| MCHR1 | Neuropsychiatric disorders (mood, arousal) | Conditional knockout in GABAergic neurons; primary cilia imaging |
| MCHR1 | Nicotine dependence and locomotor behavior | Pharmacological antagonism in rats; sex-specific behavioral assays |
| PMCH | Energy balance and feeding | PMCH knockout mice; MCH infusion studies |
| NTS | Arousal and locomotor activity | Neurotensin infusion with MCHR1 antagonists |
Obesity and Metabolic Disorders
MCHR1 signaling promotes feeding and weight gain, and MCHR1 antagonists have been developed as anti-obesity agents. The receptor's expression in brown adipose tissue further links it to thermogenesis and energy expenditure. Dysregulation of MCHR1 activity may contribute to metabolic syndrome and related disorders.
Neuropsychiatric and Mood Disorders
MCHR1 is expressed in dorsal raphe neurons, where it localizes to primary cilia and may influence serotonergic signaling. MCH signaling modulates arousal and reward-related behaviors, and its inhibition by neurotensin affects locomotor activity. These findings implicate MCHR1 in mood regulation and addiction-related behaviors.
Movement and Locomotor Disorders
Conditional deletion of MCHR1 from GABAergic neurons increases locomotor activity, suggesting a role in motor control. Nicotine experience-dependent locomotor behavior is also attenuated by MCHR1 antagonism, linking the receptor to dopaminergic circuits. These observations raise the possibility that MCHR1 dysregulation contributes to hyperkinetic or reward-seeking disorders.
From melanin-concentrating hormone receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does MCHR1 mediate locomotor activity? | Conditional MCHR1 knockout from GABAergic neurons |
| How does MCHR1 signaling affect energy expenditure? | MCHR1 knockout mice in brown adipose tissue studies |
| What is the role of MCHR1 in primary cilia? | Tagged knock-in of MCHR1 with ciliary markers |
| How does nicotine experience alter MCHR1 function? | Pharmacological antagonism in male and female rats |
| Can MCHR1 antagonists be optimized for safety? | Point mutations in MCHR1 to assess ligand binding and hERG liability |
| Does neurotensin inhibit MCH signaling? | Overexpression of NTSR1 in MCHR1-expressing cells |
How to Study the melanin-concentrating hormone receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Receptor affinity and density | Characterizing MCHR1 ligands |
| cAMP assay | Gi/o-mediated inhibition of adenylyl cyclase | Measuring MCHR1 activation |
| Calcium mobilization | Gq-mediated calcium release | Assessing MCHR1 signaling |
| Immunofluorescence | Subcellular localization (cilia, membrane) | Studying MCHR1 trafficking |
| Locomotor activity monitoring | Behavioral output | Evaluating MCHR1 function in vivo |
| Energy expenditure | Metabolic rate | Linking MCHR1 to thermogenesis |
| CRISPR knockout | Gene function loss | Validating MCHR1 in cell models |
| RNA-seq | Transcriptional changes | Identifying downstream pathways |
Receptor Binding Assays
Radioligand binding assays using tritiated MCH or MCHR1 antagonists measure receptor affinity and density in tissues or transfected cells. These assays are foundational for characterizing GO:0030273 activity and for screening small-molecule modulators.
Signal Transduction Assays
cAMP inhibition, calcium mobilization and reporter gene assays quantify downstream signaling upon MCHR1 activation. These methods distinguish G protein coupling preferences and can be adapted to high-throughput screening.
Imaging and Localization Studies
Immunofluorescence and live-cell imaging with tagged MCHR1 reveal plasma membrane and primary cilia localization. These techniques are essential for understanding compartmentalized signaling and receptor trafficking.
Behavioral and Metabolic Phenotyping
Locomotor activity monitoring, feeding studies and energy expenditure measurements in knockout or antagonist-treated animals link MCHR1 function to whole-organism physiology. Sex-specific effects should be considered in experimental design.
How CRISPR Can Be Used to Study GO:0030273 melanin-concentrating hormone receptor activity
Knockout
CRISPR-Cas9 knockout of MCHR1 in cell lines or primary neurons abolishes receptor activity, enabling loss-of-function studies on downstream signaling and behavior. Conditional knockout in GABAergic neurons has revealed increased locomotor activity, demonstrating cell-type-specific roles.
Point Mutation
Point mutations in MCHR1 can be introduced to dissect ligand-binding residues, G protein coupling interfaces or phosphorylation sites. Such models help validate structure-activity relationships and predict drug resistance mutations.
Knock-in
Knock-in of tagged MCHR1 (e.g., fluorescent or epitope tags) allows real-time visualization of receptor trafficking and ciliary localization without altering endogenous regulation. This approach is valuable for studying receptor dynamics in primary cilia.
Overexpression
Overexpression of MCHR1 in heterologous cells or specific brain regions amplifies signaling for biochemical assays and behavioral studies. It is particularly useful for testing antagonist efficacy and for mapping downstream effectors.
How EDITGENE Supports melanin-concentrating hormone receptor activity Research
Researchers studying melanin-concentrating hormone receptor activity-related genes often need to determine whether a candidate gene is causally involved in receptor signaling, energy balance or behavior. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this discovery process, from gene knockout to precise point mutations and knock-in models.
Contact EDITGENE today to design your custom CRISPR model for melanin-concentrating hormone receptor activity research.
Frequently Asked Questions About melanin-concentrating hormone receptor activity
What is melanin-concentrating hormone receptor activity?
It is the molecular function defined by GO:0030273, where a receptor binds the cyclic peptide hormone MCH to initiate changes in cell activity, primarily mediated by MCHR1.
What genes are involved in melanin-concentrating hormone receptor activity?
Key genes include MCHR1 (the receptor), PMCH (the hormone precursor), and downstream signaling genes such as GNAQ, GNAI1 and PLCB1.
Where is MCHR1 expressed?
MCHR1 is expressed in the brain, including dorsal raphe neurons, and in peripheral tissues such as brown adipose tissue.
What diseases are linked to MCHR1?
MCHR1 has been linked to obesity, metabolic syndrome, and neuropsychiatric conditions affecting arousal and reward.
How is MCHR1 signaling regulated?
It is regulated by neurotensin, nicotine experience, and receptor desensitization mechanisms involving beta-arrestins.
What is the role of MCHR1 in primary cilia?
MCHR1 localizes to primary cilia of dorsal raphe neurons, suggesting compartmentalized signaling that may influence mood.
Can MCHR1 be targeted for obesity treatment?
Yes, MCHR1 antagonists have been developed as potential anti-obesity agents, with optimization for low hERG activity.
What animal models are used to study MCHR1?
Conditional knockout mice, pharmacological antagonism in rats, and transgenic models are commonly used.
How does neurotensin affect MCH signaling?
Neurotensin enhances locomotor activity and arousal while inhibiting MCH signaling, indicating cross-talk between these systems.
What CRISPR models are available for MCHR1 research?
Knockout, point mutation, knock-in and overexpression models can be generated to study MCHR1 function and signaling.
Conclusion
Melanin-concentrating hormone receptor activity (GO:0030273) is a critical molecular function that links the cyclic peptide hormone MCH to diverse physiological processes, including energy balance, locomotion and arousal. The primary receptor MCHR1 is a well-characterized GPCR with important roles in health and disease, making it a prime target for therapeutic development. Advances in CRISPR-based models, imaging and behavioral assays continue to unravel the complexities of MCHR1 signaling, including its regulation by neurotensin and its localization to primary cilia. EDITGENE's suite of gene editing services supports researchers in dissecting these mechanisms and translating findings into novel treatments for metabolic and neuropsychiatric disorders.
References
- 1. Philippe C et al.. 2021. Discovery of melanin-concentrating hormone receptor 1 in brown adipose tissue.. Ann N Y Acad Sci 1494(1):70-86 PMID: 33502798
- 2. Kuebler IRK et al.. 2023. Melanin-concentrating hormone receptor antagonism differentially attenuates nicotine experience-dependent locomotor behavior in female and male rats.. Pharmacol Biochem Behav 232:173649 PMID: 37793486
- 3. Levitas-Djerbi T et al.. 2020. Neurotensin Enhances Locomotor Activity and Arousal and Inhibits Melanin-Concentrating Hormone Signaling.. Neuroendocrinology 110(1-2):35-49 PMID: 31030196
- 4. Chee MJ et al.. 2019. Conditional deletion of melanin-concentrating hormone receptor 1 from GABAergic neurons increases locomotor activity.. Mol Metab 29:114-123 PMID: 31668382
- 5. Niño-Rivero S et al.. 2019. Melanin-concentrating hormone receptor-1 is located in primary cilia of the dorsal raphe neurons.. J Chem Neuroanat 98:55-62 PMID: 30943431
- 6. Judd AS et al.. 2008. Lead optimization of melanin concentrating hormone receptor 1 antagonists with low hERG channel activity.. Curr Top Med Chem 8(13):1152-7 PMID: 18782010
- 7. Saito Y et al.. 2006. Identification of melanin-concentrating hormone receptor and its impact on drug discovery.. J Exp Zool A Comp Exp Biol 305(9):761-8 PMID: 16902961
- 8. Helal MA et al.. 2023. Structure-based design of novel melanin-concentrating hormone receptor-1 ligands based on saturated nitrogen-containing heterocycles.. Bioorg Med Chem Lett 84:129194 PMID: 36813053
